Visit Nektar Therapeutics

We are pleased to welcome Dr. Dimitry S.A. Nuyten as our SVP, Chief Medical Officer. He brings extensive experience establishing and executing clinical strategy for #oncology and #immuno-oncology programs across all stages of development. Read more: https://t.co/PwHI07mMIH https://t.co/1BiIjNQ1Gf

Thank you to @STEMSaturdaysf for hosting a fantastic event this past weekend celebrating #STEM with diverse young members of our community and their families! Learn more about #stemsaturdaysf: https://t.co/BFAmcGXYWk https://t.co/ZwT0W7Ksh8

We are excited to be part of the first @STEMSaturdaysf festival to inspire the next generation of #STEM leaders. Join us tomorrow in exploring polymer science via balloon skewer experiments and slime making. https://t.co/BFAmcGXYWk #stemsaturdaysf https://t.co/XHlvCfCY5E

We are excited that John Hayslip, M.D., joined as VP of Clinical Development. He has 15+ years of experience overseeing clinical trials in biopharma and academic settings and will be instrumental as we advance our pipeline. Learn more: https://t.co/5pOgS2s3av #drugdevelopment https://t.co/JaQcskaoCN

Our Ph II study of BEMPEG plus NIVO is featured in @ASCO_Pubs Journal of Clinical Oncology. This #JCO publication highlights encouraging safety and efficacy data in patients with first-line metastatic #melanoma. View here: https://t.co/6syhdYVfJ2 #immunotherapy https://t.co/XbfbPiEKMP

Nektar honors patients and families this #CIM21 and throughout the year as we leverage the power of immunotherapy to improve treatment for a broad range of solid tumors and blood cancers. Learn more about our R&D programs: https://t.co/zPoCrgKvWo #immune2cancer https://t.co/M7KWZ9ODmJ

At Nektar, we’re leveraging pathways that activate the immune system to fight #cancer. To learn more about our cancer programs targeting the IL-2, IL-15 and TLR 7/8 pathways, visit: https://t.co/O9gxFxdSiw #CIM21 https://t.co/E8vf2pUJRj

Thank you, @jitcancer, for selecting our manuscript on NKTR-255 as a JITC Editorial Pick! To read more about this research, view our recent press release: https://t.co/spF6WRkelK #immunotherapy #immune2cancer https://t.co/yk2ZvcQk2i

This #CancerImmunotherapyMonth, we’re sharing our appreciation for @CancerResearch and its leadership in creating a future #immune2cancer. View the organization’s #immunotherapy resources: https://t.co/GbjSIK7QV3 https://t.co/3AT5RfAm12

Our ongoing Ph I NKTR-255 trial design is featured in @FutureOncol_FSG. The study will evaluate this natural killer cell mechanism in combination with targeted antibodies in hematological malignancies. View here: https://t.co/vEEyKZvAbd #cancer #immunotherapy https://t.co/UzHj7qrxCu

We are thrilled to hear all the innovative discussions happening at this year’s #BIODigital 2021 and to see so many of our industry colleagues – hope to see you in person next year! #lifesciences #patientdriven https://t.co/XRUjPFVLTK

We’re excited to collaborate with @BMSnews on a new clinical trial with @ExelixisInc that includes bempegaldesleukin for the development of potential therapies for patients with advanced clear cell RCC and other solid tumors. For more info: https://t.co/Uo4KWvPFMm #immune2cancer

We are pleased to share the publication of preclinical data in the Journal of Translational Autoimmunity demonstrating NKTR-358’s #immune mediation properties. Read more: https://t.co/Z9HSGu8v7b https://t.co/Iz9AtdMBCu

Takahiro Miyazaki, our VP, Head of Research, shares insights on our recent @jitcancer publication and the potential of NKTR-255 as a treatment for blood #cancer and solid #tumors. Read here: https://t.co/PPA2bvOKyf

We are pleased to share the publication of preclinical data in @jitcancer demonstrating NKTR-255’s pharmacologic and anti-#tumor properties. Learn more: https://t.co/AwquaxypRz https://t.co/RxV3PctWuS

Thanks to #10thWCM for a great meeting and to our collaborators for presenting data from studies of BEMPEG, our #immunotherapy candidate for the treatment of #melanoma. Explore the poster presentations on our website: https://t.co/fgiLXXHH7z https://t.co/qnBE1ohxjy

Dr. Diab, Dr. Eggermont and Dr. Muhsin share some exciting research Nektar is doing in melanoma at #10thWCM. Learn more here: https://t.co/fgiLXXHH7z $NKTR https://t.co/c9HBKj4ATB

Nektar is proud to support the 2021 SITC-Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy #SITCFellowship. #ApplyToday: https://t.co/NMqSQ4xrya https://t.co/elrKKiOnSP

Nektar supports diversity and the opportunity that the 2021 SITC-Nektar Equity and Inclusion in Cancer Immunotherapy Fellowship provides. Applications are due April 2nd #ApplyToday: https://t.co/NMqSQ4xrya #SITCFellowships https://t.co/6KynYcjuE8

Nektar is proud to sponsor #SFBTwomenwholead and recognize women leaders in life sciences. Hear from Mary Tagliaferri, executive clinical fellow and SVP, how Nektar is getting involved. https://t.co/qTslkY3eOb